Xillix Wins Award for Most Promising Life Science Technology
RICHMOND, BRITISH COLUMBIA--On September 20, 2002, Xillix
Technologies Corp. received the Investors' Choice Award for the
most promising life science technology after presenting at the 4th
Annual Pacific Northwest Venture Capital Forum, an event hosted by
The Monte Jade Science & Technology Association. The forum was
comprised of life science and information technology companies
presenting their cutting edge technology to venture capitalists,
industry peers and other executives. Sponsors of the event
included: Business Development Bank of Canada; BC Technology
Industries Association; BC Ministry of Competition, Science and
Enterprise; Cansbridge Capital Corp; Comerica; Cooley Godward,
L.L.P; Clark, Wilson; Deloitte & Touche; Ernst & Young; Fasken
Martineau; Getz Prince Wells; GrowthWorks; MDS Capital Corp.;
TieUs Technology; and TVCA.
"We are delighted to be recognized for our technology. Winning
this award is a tremendous vote of confidence from the investment
community, especially as we are working to complete our recent
financing activities," said Cynthia Roney, President & CEO.
"We are pleased to present the prestigious Investors' Choice Award
to Xillix Technologies from a field of strong contenders. The
attending venture capitalists were impressed with the company's
business case and presentation style," said William Yu, Chair of
Monte Jade. Previous year's presenting companies and award
winners went on to raise over CDN $100M during the last 12 months.
The Monte Jade Science & Technology Association is a non-profit
trade association for the producers and users of technology in all
sectors of the economy. On behalf of its membership, Monte Jade
promotes and facilitates the development of a strong commercial
technology industry globally. With 12 chapters throughout the
world, over 2,500 individual members and roughly 500 corporate
members, Monte Jade's forums help to link entrepreneurship and
investment capital to create new business opportunities.
Xillix LIFE(TM) fluorescence-based medical imaging technology
helps physicians diagnose early-stage lung and gastrointestinal
(GI) cancers. By exposing tissue to light from Xillix's patented
fluorescence imaging device, physicians may be better able to
detect pre-cancerous and cancerous cells. In 1996, clinical
studies approved by the U.S. Food and Drug Administration (FDA)
confirmed that Xillix's first-generation lung device, the Xillix
LIFE-Lung System(TM) improved physicians' ability to detect lung
cancer by 171% compared with conventional white light bronchoscopy
alone. Xillix is preparing its latest device, Onco-LIFE(TM), for
clinical trials to prove its value in detecting and localizing
early lung and GI cancers. This new device leverages Xillix's
worldwide experience and innovation. Onco-LIFE is compact,
affordable, easy-to-use and incorporates both fluorescence and
conventional imaging in a single system that will 'plug and play'
with a wide range of endoscopes and endoscopic accessories to
maximize global market acceptance. |
